Apogenix to Present at Several Upcoming International Conferences
ACCESS Newswire
10 Oct 2019, 13:49 GMT+10
HEIDELBERG, GERMANY / ACCESSWIRE / October 10, 2019 / Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will attend several upcoming international conferences. In two presentations, Apogenix will give updates on TNF superfamily receptor agonists HERA-CD40L and HERA-GITRL. The company will further present a poster on the therapeutic benefit of orphan drugs in oncology.
Festival of Biologics (October 15-17, 2019)
Venue: Congress Center Basel, Basel, Switzerland
Attendees: Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering; Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization; Meinolf Thiemann, Ph.D., Director Protein Analytics
Presentation by Dr. Hill on October 16, 12:05 pm: 'HERA-CD40L: A Unique Hexavalent CD40 Agonist for Cancer Immunotherapy'
ISPOR Europe 2019 (November 2-6, 2019)
Venue: Bella Center Copenhagen, Copenhagen, Denmark
Attendee: Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment
Poster Presentation on November 4, 3:30 - 7:00 pm (Poster Author Discussion Hour: 6:00 - 7:00 pm): 'Therapeutic Benefit of Orphan Drugs in Oncology: Evidence at the Point of European Marketing Authorisation'
BIO-Europe 2019 (November 11-13, 2019)
Venue: Hamburg Messe, Hamburg, Germany
Attendees: Juergen Gamer, Ph.D., VP Business Development; Niclas Kneisel, Ph.D., Alliance Manager
11th Annual PEGS Europe (November 18-22, 2019)
Venue: Lisbon Congress Centre, Lisbon, Portugal
Attendees: Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering; Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization
Presentation by Dr. Hill on November 22, 2:35 pm: 'HERA-GITRL: A Unique Hexavalent GITR Agonist for Cancer Immunotherapy'
About Apogenix
Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of solid tumors and hematological malignancies. The company's pipeline of immuno-oncology drug candidates targets different tumor necrosis factor (TNF) superfamily-dependent signaling pathways, thereby restoring the immune response against tumors. Checkpoint inhibitor asunercept, the company's lead immuno-oncology candidate, is in late-stage clinical development with PRIME (PRIority MEdicines) designation by the European Medicines Agency for the treatment of glioblastoma. Based on its proprietary technology platform for the construction of novel TNF superfamily receptor agonists (HERA-ligands), Apogenix develops CD40, CD27, GITR, HVEM, and 4-1BB receptor agonists for cancer immunotherapy. The TRAIL receptor agonist program was outlicensed to AbbVie. AbbVie has initiated a phase I trial with TRAIL receptor agonist ABBV-621 in patients suffering from solid tumors, non-Hodgkins's lymphoma, or acute myeloid leukemia.
Contacts
Peter Willinger, CFO
Jennifer Mogk, PR Manager
Apogenix AG
Phone: +49 6221 58608-0
E-Mail: [email protected]
Web: www.apogenix.com
Media Contacts
Katja Arnold
Andreas Jungfer
MC Services AG
Phone: +49 89 210228-0
E-Mail: [email protected]
SOURCE: Apogenix
View source version on accesswire.com:
https://www.accesswire.com/562687/Apogenix-to-Present-at-Several-Upcoming-International-Conferences
Share
Tweet
Share
Flip
Email
Subscribe and Follow
Get a daily dose of Hawaii Telegraph news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
News RELEASES
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Hawaii Telegraph.
More InformationTravelers can now keep shoes on at TSA checkpoints
WASHINGTON, D.C.: Travelers at U.S. airports will no longer need to remove their shoes during security screenings, Department of Homeland...
Rubio impersonator used AI to reach officials via Signal: cable
WASHINGTON, D.C.: An elaborate impersonation scheme involving artificial intelligence targeted senior U.S. and foreign officials in...
Warsaw responds to migration pressure with new border controls
SLUBICE, Poland: Poland reinstated border controls with Germany and Lithuania on July 7, following Germany's earlier reintroduction...
Deadly July 4 flash floods renew alarm over NWS staffing shortages
WASHINGTON, D.C.: After months of warnings from former federal officials and weather experts, the deadly flash floods that struck the...
Putin fires transport chief, later found dead in suspected suicide
MOSCOW, Russia: Just hours after his sudden dismissal by President Vladimir Putin, Russia's former transport minister, Roman Starovoit,...
Thousands gather in Himalayas as Dalai Lama celebrates 90th birthday
DHARAMSHALA, India: The Dalai Lama turned 90 on July 6, celebrated by thousands of followers in the Himalayan town of Dharamshala,...
Gold ETF inflows hit 5-year high as tariffs drive safe-haven bets
LONDON, U.K.: Physically backed gold exchange-traded funds recorded their most significant semi-annual inflow since the first half...
PwC: Copper shortages may disrupt 32 percent of chip output by 2035
AMSTERDAM, Netherlands: Some 32 percent of global semiconductor production could face climate change-related copper supply disruptions...
U.S. stocks recover after Trump-tariffs-induced slump
NEW YORK, New York - U.S. stocks rebounded Tuesday with all the major indices gaining ground. Markets in the UK, Europe and Canada...
Stocks slide as Trump unveils 25% tariffs on Japan, S. Korea
NEW YORK CITY, New York: Financial markets kicked off the week on a cautious note as President Donald Trump rolled out a fresh round...
BRICS issues rebuke on trade and Iran, avoids direct US criticism
RIO DE JANEIRO, Brazil: At a two-day summit over the weekend, the BRICS bloc of emerging economies issued a joint declaration condemning...
BP appoints ex-Shell finance chief Simon Henry to board
LONDON, U.K.: This week, BP appointed Simon Henry, former Shell finance chief, to its board as a non-executive director effective September...
